Sistema de Salut de Catalunya
Institut Català de la Salut
[Tchang BG] Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, USA. [Ciudin Mihai A] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Stefanski A, García-Pérez LE, Mojdami D, Jouravskaya I] Eli Lilly and Company, Indianapolis, Indiana, USA
Vall d'Hebron Barcelona Hospital Campus
2025-05-06T10:04:37Z
2025-05-06T10:04:37Z
2025-05
Body weight reduction; Women; Reproductive stage
Reducción del peso corporal; Mujeres; Etapa reproductiva
Reducció del pes corporal; Dones; Etapa reproductiva
Objective Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage. Methods Women participants from SURMOUNT-1, -3, and -4 randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo were retrospectively categorized as being in the pre-, peri-, or post-menopause stages. Body weight and waist circumference changes, the proportion of participants achieving body weight-reduction thresholds, and waist to height ratio (WHtR) category shift among those with baseline BMI < 35 kg/m2 were assessed at end of study treatment. Results In SURMOUNT-1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001). Greater waist circumference reductions were also observed with tirzepatide across the subgroups (22 vs. 4 cm, 20 vs. 5 cm, and 20 vs. 4 cm, respectively; p < 0.001). Across the reproductive stage subgroups, 97% to 98% of participants achieved body weight reductions that were ≥5% with tirzepatide versus 29% to 33% with placebo. Furthermore, 30% to 52% of women among the reproductive stage subgroups who had baseline BMI < 35 kg/m2 reached WHtR ≤ 0.49 (low central adiposity) with tirzepatide. Similar results were observed in SURMOUNT-3 and -4. Conclusions In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage.
Funding for this post hoc analysis was provided by Eli Lilly and Company.
Article
Published version
English
Dones; Menopausa; Tractaments d'aprimament; Aprimament; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Obesity Agents; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss; PHENOMENA AND PROCESSES::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause; PHENOMENA AND PROCESSES::Physiological Phenomena::Body Constitution::Body Composition::Body Fat Distribution::Adiposity; NAMED GROUPS::Persons::Women; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos antiobesidad; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::peso corporal::cambios en el peso corporal::pérdida de peso; FENÓMENOS Y PROCESOS::fenómenos fisiológicos reproductivos y urinarios::fenómenos fisiológicos de la reproducción::climaterio::menopausia; FENÓMENOS Y PROCESOS::fenómenos fisiológicos::constitución corporal::composición corporal::distribución de la grasa corporal::adiposidad; DENOMINACIONES DE GRUPOS::personas::mujeres
Wiley
Obesity;33(5)
https://doi.org/10.1002/oby.24254
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
